logo
Share SHARE
FONT-SIZE Plus   Neg

MyoKardia Inc. (MYOK) Is Surging On Phase 2 Study Results

MyoKardia Inc. (MYOK) announced Monday morning that its Phase 2 PIONEER-HCM study of mavacamten in symptomatic, obstructive hypertrophic cardiomyopathy patients met its primary endpoint.

MyoKardia has gapped open dramatically higher this morning and is now up 9.65 at $26.80 on strong volume. The stock has surged to a new high for the year.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

comments powered by Disqus
Follow RTT